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INTRODUCTION:  Breast  sarcomas  are  rare  with  an  annual  incidence  of  4.6 cases/1,000,000  women.  They
can  appear  as  primary  forms  or secondary  to radiation  therapy  or chronic  lymphedema.
PRESENTATION  OF  CASE:  A 41  year  old woman  attended  our  hospital  after  having  noticed  an increase  in
the size  of her  ﬁbroadenoma.  The  examination  revealed  a 7  cm retroareolar  nodule.  Breast  sonography
described  a hypoechoic  bilobulated  lesion  and MRI  showed  a large  size  polinodular  image,  suggesting  a
Phyllodes  tumor.  A core  needle  biopsy  was  performed  with  a histological  result of low-grade  fusiform
cells  sarcoma  on Phyllodes  tumor  so we  proceeded  to surgical  treatment  with  a mastectomy.
After  two  years  and  a  half  she  noticed  a tough  nodule  over  the mastectomy  scar,  which  was  resected
with  a histological  result  of  fusiform  cells  sarcoma.  Considering  the  diagnosis  of  recurrence  of  the  disease,
surgery  was  undertaken.
DISCUSSION:  Breast  sarcoma  is  a rare but aggressive  entity.  Core  biopsy  is the  procedure  of  choice  for  the
diagnosis.  Lymphatic  spread  is  uncommon  so  nodal  status  in  breast  sarcoma  is  less informative.  Staging
study  differs  from  other  breast  tumors  and  chest  computed  tomography  is  helpful  since  lungs  are  the
predominant  metastatic  sites.  The  use of  radiotherapy  or  chemotherapy  is controversial  and  will depend
on the risk  of  tumor  recurrence.
CONCLUSION:  Surgery  represents  the only  potentially  curative  therapy  for breast  sarcoma.  Tumor  size and
adequate resection  margin  are  the  most  important  prognostic  factors.  Approximately  80%  of  recurrences
appear  in  the  ﬁrst  two  years.
©  2016  Published  by  Elsevier  Ltd on  behalf  of  IJS  Publishing  Group  Ltd.  This  is  an  open  access  article
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. Introduction
Breast sarcomas, which develop from mesenchymal tis-
ue, are rare and their annual incidence is approximately 4.6
ases/1,000,000 women, representing less than 1% of all breast
alignancies. They can appear as primary forms (de novo) or sec-
ndary to chronic lymphedema or radiation therapy on the breast
r chest wall, with the two forms presenting different features. The
rimary forms appear histologically as heterogenous subtypes and
heir mean age of diagnosis is around 40 years. In contrast, the sec-
ndary forms typically present later at around 45–50 years and the
ost common histological subtype is angiosarcoma.
Lymph node metastases are uncommon in breast sarcomas and
urgery represents the only potentially curative therapy, always
ith an adequate resection margin.
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They can share some clinical features with breast carcinomas
but therapy and prognosis can differ substantially.
We present this case because of the low incidence of breast sar-
comas with few cases being reported, especially of primary forms,
and the clinical imagery obtained.
2. Presentation of case
A 41 year old woman, who  had been diagnosed previously with a
ﬁbroadenoma on the left breast, attended our hospital after having
noticed an increase in its size. Her personal history did not feature
other important details. The examination revealed a 7 cm retroare-
olar nodule, well-deﬁned and tough. Breast ultrasound described
the previously known ﬁbroadenoma and a hypoechoic bilobulated
lesion with thick margins (Fig. 1) and the result of the citology
we obtained by ﬁne needle aspiration was  connective-adipose
tissue. The MRI  showed a large size polinodular image, without
signs of necrosis or haemorrhage, suggesting a possible Phyllodes
tumor (Fig. 2). The images revealed a low diffusion and a rapid
contrast-enhancement with a posterior plateau. We  decided to per-
form a core needle biopsy with a histological result of low-grade
fusiform cells sarcoma on Phyllodes tumor. As a consequence of
s an open access article under the CC BY-NC-ND license (http://creativecommons.
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Fig. 1. A 55 mm hypoechoic bilobulated lesion with thick margin.
Fig. 2. MRI.
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There is some controversy about the use of radiotherapy orFig. 3. Reconstruction.
hese results, we made a staging study on the disease extent by a
horacic and abdominal scanner without signs of disease spread, so
e proceeded to surgical treatment with a mastectomy of the left
reast and posterior reconstruction with prosthesis (Fig. 3).Fig. 4. Recurrence.
After two and a half years of close monitoring, she came again
to our hospital because of a tough nodule over the mastectomy
scar and the breast ultrasound revealed a heterogeneous epider-
mic  nodule of 19 mm (Fig. 4). It was  resected and the histological
result showed fusiform cell sarcoma. Considering the diagnosis of
recurrence of the disease, surgical treatment was performed with
an enlargement of tumor margins, resecting the pectoral muscle
and removing the prosthesis.
3. Discussion
Breast sarcoma is a rare but aggressive entity. Due to its rarity,
there have not been sufﬁcient studies of its clinicopathological fea-
tures and adequate treatment approach to achieve a consensus in
terms of management of the disease, with published articles usually
being small retrospective case reports and reviews.
In most cases, the etiology is unknown and although women
who receive radiotherapy have an increased risk of presenting sec-
ondary breast sarcoma, the absolute incidence is small.
Clinically it appears as a unilateral, well-deﬁned and large mass;
it often grows faster than epithelial breast carcinoma. It can be sus-
pected with a physical examination or through imaging tools, but
core biopsy is required for diagnosis [1].
With regard to imaging, either breast ultrasound, mamography
or MRI  can be useful. The feature usually found in the imagery is the
presence of a mass with irregular margins with or without calciﬁ-
cations. It appears to be frequently hypoechoic at ultrasound and
T2 hyperintense at MRI  [2,3].
Lymphatic spread is uncommon in this entity, and dissemina-
tion usually occurs haematogenously and the principal organs to be
metastasized are lungs, bones and liver. This is why  sentinel lymph
node biopsy has not been studied in these cases, as it does not seem
to offer sufﬁcient beneﬁt to the patient or to prompt a change in
clinical management. Consequently, this means that staging stud-
ies will differ from other breast tumors due to the fact that nodal
status in breast sarcoma is less informative, so in these cases chest
computed tomography is helpful for staging since lungs are the
predominant metastatic sites.
Surgery is the standard treatment. Tumor size and adequate
resection margin are the most important prognostic factors; in fact,
an adequate resection margin is the most important determinant
of long-term survival. Rutinary lymphadenectomy does not seem
to improve outcomes [4,5].chemotherapy in these patients, so there is no consensus as to the
use of adjuvant therapy and it will depend mainly on the risk of
tumor recurrence. Taking this into account, the use of radiotherapy
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eems to be recommended after positive margin resection due to
he high risk of recurrence and those cases in which a R0 resec-
ion is achieved but tumors are larger than 5 cm or there is a high
rade sarcoma. Prior to radiotherapy, chemotherapy is based on the
oxorubicin and Ifosfamide scheme, however there is no evidence
upporting their use as response rates of breast sarcoma seem to be
imited [1,4]. A close follow-up is recommendable during the ﬁrst
wo years because approximately 80% of recurrences appear in this
eriod.
In the present case, the initial surgery involving mastectomy and
chieving negative resection margins (R0) in a low grade tumor
ed us to dismiss other adjuvant treatment because of the afore-
entioned controversy about these therapies. However, once the
iagnosis of local recurrence of the disease was conﬁrmed, we  rec-
mmended completing the surgical treatment with an enlargement
f tumor margins and undergoing postoperative radiation therapy
espite there being little evidence conﬁrming the latterı´s effective-
ess in improving global survival rates.
. Conclusion
Breast sarcoma is a rare but aggressive entity and core biopsy
s required for diagnosis. Unlike with epithelial breast carcinoma,
ymphatic spread is uncommon and staging studies differ from
ther breast tumors due to the fact that nodal status in breast
arcoma is less informative. Consequently chest computed tomog-
aphy is helpful since lungs are the predominant metastatic sites.
urgery represents the only potentially curative therapy in these
ases, and tumor size and adequate resection margin are the most
mportant prognostic factors. Some controversy still exists about
he use of radiotherapy or chemotherapy, which is why  currently
he use of adjuvant therapy is usually limited to cases with high risk
f recurrence due to positive margin resection, tumors larger than
 cm or a high grade sarcoma. A close follow-up is recommendable
uring the ﬁrst two years, when approximately 80% of recurrences
ppear.
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